MedTrace Logo

Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)

NCT07615179 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2214

Last updated 2026-05-29

No results posted yet for this study

Summary

The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.

Conditions

  • Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

Interventions

DRUG

Alirocumab

The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

DRUG

Comparator: No PCSK9i Therapy (either mAb or siRNA)

The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2026-05-30
Completion
2026-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07615179 on ClinicalTrials.gov